Combating infections in hematopoietic stem cell transplant recipients

References

• Petersen F, Thornquist M, Buckner C, etal. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 16, 99–208 (1988).
   Web of Science ®Google Scholar
• Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 6, 659–713, 715, 717–627 (2000).
   Web of Science ®Google Scholar
• •• This paper provides evidence-based recommendations regarding prophylactic medications, infection control measures and vaccination strategies for the prevention of serious infections after HSCT and is a product of the collaboration of the CDCP, the Infectious Diseases Society of America and the American Society for Blood and Marrow Transplantation.
   Google Scholar
• Lew MA, Kehoe K, Ritz J, et al Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial." Gun. Oncol 13, 239–250 (1995).
   Google Scholar
• De Pauw BE, Donnelly JP, De Witte T, Novakova IR, Schattenberg A. Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow 71ansplant5, 179–182 (1990).
   Google Scholar
• Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Gun. Infect. Dis. 34, 1469–1474 (2002).
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Dykewicz CA, Longworth DL, etal. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology392-421 (2001).
   Google Scholar
• Hughes WT, Armstrong D, Bodey GP, etal. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34,730–751 (2002).
   PubMed Web of Science ®Google Scholar
• ••Although these clinical guidelines do notspecifically address the unique issues surrounding HSCT recipients, they form the basis for sound decision-making in the setting of febrile neutropenia.
   Google Scholar
• Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. P-lactam versus P-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia (Cochrane Review). The Cochrane Library. Oxford. Update Software (2003).
   Google Scholar
• Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect. Dis. 29,508–514 (1999).
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Walsh T, Marshall D, etal.Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. j Clin. Oncol 13,165–176 (1995).
   Web of Science ®Google Scholar
• Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-Associated diarrhea: a review. Arch. Intern Med. 161,525–533 (2001).
   PubMed Web of Science ®Google Scholar
• Turgeon DK, Novicki TJ, Quick J, etal. Six Rapid Tests for Direct Detection of Clostridium difficile and Its Toxins in Fecal Samples Compared with the Fibroblast Cytotoxicity Assay. j Clin. Microbial. 41, 667–670 (2003).
   PubMed Web of Science ®Google Scholar
• Niault M, Thomas F, Prost J, Ansari PH, Kalfon P Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin. Infect. Dis 28,930 (1999).
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, et al Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96,2055–2061 (2000).
   PubMed Web of Science ®Google Scholar
• Marr IKA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. j Infect. Dis. 181, 309–316 (2000).
   Web of Science ®Google Scholar
• Marr IKA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100, 4358–4366 (2000).
   Google Scholar
• ••In the current era of fluconazole prophylaxis and pre-emptive therapy for CMV, Marr and coworkers report that risk factors for early aspergillosis (which include cord blood or marrow as stem cell source) may differ from those associated with late disease (which include receipt of steroids for GVHD and other viral infections). Mortality from invasive aspergillosis is high regardless of time of occurrence relative to transplantation (approaching 80% 6 months after diagnosis).
   Google Scholar
• Junghanss C, Marr IKA, Carter RA, etal.Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol. Blood Marrow Tiamplant. 8, 512–520 (2002).
   PubMed Web of Science ®Google Scholar
• •Junghanss and colleagues report that the incidence of bacteremia during the first 30 days after transplantation is lower in recipients of non-myeloablative HSCT than in recipients of myeloablative transplants (9 versus 27%) but invasive aspergillosis occurs at a similar rate (15 versus 9%).
   Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, etal. Long-term antifungal prophylaxis in allogeneic bone marrow transplant patients: a multicenter, randomized trial of intravenous /oral itraconazole versus intravenous/oral fluconazole. Blood 98, 479a (2001).
   Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, etal. Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT recipients: results of a randomized trial. Blood 100, 215a (2002).
   Web of Science ®Google Scholar
• van Burik JA, Ratanatharathom V, Lipton J, Miller C, Bunin N, Walsh TJ. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant, NIAID/BAMSG Protocol 46 (Abstract M-1238). Program and Abstracts from 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA 401 (2002).
   Google Scholar
• Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Co-operative Group. Am. j Med. 86,668–672 (1989).
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, Witebsky PG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. j Med. 72,101–111 (1982).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. j. 114ed. 108,282-289 (2000).
   Google Scholar
• Boogaerts M, Winston DJ, Bow EJ. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med. 135, 412–422 (2001).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl. I Merl 340,764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. I Merl 346, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Alexander BD. Diagnosis of fungal infection: new technologies for the mycology laboratory. Bans*. Infect. Dis. 3(4 Suppl.) 32–37 (2002).
   Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl.J. Med. 347,2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Caillot D, Couainier JF, Bernard A, etal. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. j Clin. aryl 19, 253–259 (2001).
   Google Scholar
• Buchheidt D, Baust C, SIdadny H, Baldus M, Brauninger S, Hehlmann R. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. BE j Haematol. 116, 803–811 (2002).
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97,1604–1610 (2001).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DVV, Patterson TF, etal. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl. I Med. 347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• ••In a randomized controlled trial of 277patients with invasive aspergillosis, favorable responses at week 12 after randomization occurred in 53% of patients initially treated with voriconazole vs. only 32% of patients treated with amphotericin B. Most importantly, survival was also superior in the voriconazole arm = 0.015
   Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46, 245–247 (2002).
   PubMed Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46, 3039–3041 (2002).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TE Efficacy of caspofungin alone and in combination with voriconazole in a Guinea-pig model of invasive aspergillosis. Antimicrob. Agents Chemothec 46, 2564–2568 (2002).
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, et al Refractory Aspergillus pneumonia in patients with acute leukemia. Cancer 97, 1025–1032 (2003).
   PubMed Web of Science ®Google Scholar
• Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol. Blood Marrvw Transplant (7 Suppl.) 115–155 (2001).
   Google Scholar
• Bowden RA, Slichter SJ, Sayers M, et al A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments]. Blood 86, 3598–3603 (1995).
   PubMed Web of Science ®Google Scholar
• Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood16 [epub ahead of print] (2002).
   Google Scholar
• Holmberg LA, Boeckh M, Hooper H, et al Increased incidence of cytomegalovirus disease after autologous CD34-selectedperipheral blood stem cell transplantation. B/ooc/94, 4029–4035 (1999).
   Google Scholar
• Junghanss C, Boeckh M, Carter RA, et al Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99, 1978–1985 (2002).
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R, etal. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99, 4357–4363 (2002).
   PubMed Web of Science ®Google Scholar
• Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 93,1781-1782 (letter) (1999).
   Google Scholar
• Nichols WG, Corey L, Gooley T, etal. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load and outcomes. Blood 97, 867–874 (2001).
   PubMed Web of Science ®Google Scholar
• •Demonstrated that rising CMV viral load on pre-emptive therapy occurs in up to a third of patients early after HSCT; this is not associated with antiviral resistance but with the level of imrnunosuppression. Patients who received higher doses of antivirals (i.e., induction dosing) in response to rising viral load appeared to have a lower incidence of breakthrough CMV disease.
   Google Scholar
• Reusser P, Einsele H, Lee J, et al Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99,1159–1164 (2002).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Deliliers GL, Platzbecker U, et al Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97, 388–392 (2001).
   PubMed Web of Science ®Google Scholar
• Leather HL, Meyer CL, Wingard JR. Oral valganciclovir for preemptive therapy of cytomegalovirus antigenemia in hematopoietic stem cell transplant recipients. Biol. Blood Man ow Transplant 9, 132 (2003) (Abstract 238).
   Google Scholar
• Boeckh M, Leisenring W, Riddell SR, etal. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood101, 407–414 (2003).
   Google Scholar
• Saral R, Burns WH, Laskin OL, Santos GVV, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. New Engl. Med. 305, 63–67 (1981).
   PubMed Web of Science ®Google Scholar
• Hann IM, Prentice HG, BlacIdock HA, et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double-blind trial. BE Med. Clin. Res. Ed. 287, 384–388 (1983).
   PubMed Web of Science ®Google Scholar
• Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann. Intern. Med. 100, 823–828 (1984).
   PubMed Web of Science ®Google Scholar
• Chen Y, Scieux C, Garrait V, etal. Resistant herpes simplex virus Type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin. Infect. Dis. 31, 927–935 (2000).
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. I Infect. Dis. 181, 2055–2058 (2000).
   Web of Science ®Google Scholar
• Langston AA, Redei I, Caliendo AM, et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 99, 1085–1088 (2002).
   PubMed Web of Science ®Google Scholar
• Nichols WG, Boeckh M, Carter RA, Wald A, Corey L. Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. Infect. Dis. 187, 801–808 (2003).
   Web of Science ®Google Scholar
• Bowden RA, Rogers KS, Meyers JD. Oral acyclovir for the long-term suppression of varicella-zoster virus infection after marrow transplantation. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, CA, USA, 62 (1989).
   Google Scholar
• Zerr DM, Gooley TA, Yeung L, etal. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 33, 763–771 (2001).
   PubMed Web of Science ®Google Scholar
• Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 309–317 (2002).
   PubMed Web of Science ®Google Scholar
• Wang FZ, Linde A, Hagglund H, Testa M, Locasciulli A, Ljungman P. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin. Infect. Dis. 28, 562–568 (1999).
   PubMed Web of Science ®Google Scholar
• Bethge W, Beck R, Jahn G, Mundinger P, Kanz L, Einsele H. Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation. Bone Marrow Transplant. 24,1245–1248 (1999).
   PubMed Web of Science ®Google Scholar
• Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 31,145–155 (2003).
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 91,3079–3083 (1998).
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Verschuuren EA, Verkuujlen SA, Van Den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk. Lymphoma 43,831–840 (2002).
   PubMed Web of Science ®Google Scholar
• Kuehnle I, Huls MH, Liu Z, etal. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95,1502–1505 (2000).
   PubMed Web of Science ®Google Scholar
• Van Esser J, Niesters H, Van Der Holt B, etal. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. B/ooc/. 99,4364–4369 (2002).
   Google Scholar
• Nichols WG, Guthrie IKA, Corey L, Boeckh M. Influenza infections after stem cell transplantation: risk factors, mortality and the effect of antiviral therapy. Biol. Blood Marrow Transplant. 9,73–74 (2003).
   Google Scholar
• Hayden FG, Treanor JJ, Fritz RS, etal. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAIVIA 282, 1240–1246 (1999).
   PubMed Web of Science ®Google Scholar
• Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J. Infect. Dis. 184,350–354 (2001).
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation — a compassionate use experience. Bone Marrow Transplant. 25, 161–165 (2000).
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy and effect on transplant outcome. Blood 98,573–578 (2001).
   PubMed Web of Science ®Google Scholar
• Lankester AC, van Tol MJ, Claas EC, Vossen JM, Kroes AC. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin. Infect. Dis. 34,864–867 (2002).
   PubMed Web of Science ®Google Scholar
• Echavarria M, Forman M, van Tol MJ, Vossen JM, Charache P, Kroes AC. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 358,384–385 (2001).
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, et al Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression and immune recovery. B/ooc/100,1619–1627 (2002).
   Google Scholar
• Legrand F, Berrebi D, Houhou N, etal Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 27,621–626 (2001).
   PubMed Web of Science ®Google Scholar
• Kwak EJ, Vikhez RA, Randhawa P, Shapiro R, Butel JS, Kusne S. Pathogenesis and management of polyomavirus infection in transplant recipients. Clin. Infect. Dis. 35, 1081–1087 (2002).
   PubMed Web of Science ®Google Scholar
• Leung AY, Mak R, Lie AK, etal. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow 7iansplant. 29,509-513 (2002).
   Google Scholar
• Chakrabarti S, Osman H, Collingham K, Milligan DW. Polyoma viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant. 31,379–386 (2003).
   PubMed Web of Science ®Google Scholar
• Leung AY, Suen CK, Lie AK, Liang RII, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 98,1971–1978 (2001).
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother. 41,587–593 (1997).
   PubMed Web of Science ®Google Scholar
• Gonzalez— Fraile MI, Canizo C, Caballero D, etal. Cidofovir treatment of human polyomavirus—associated acute haemorrhagic cystitis. 7iansplant. Infect. Dis. 3,44-46 (2001).
   Google Scholar
• Held TK, Biel SS, Nitsche A, Kurth A, Chen S, Gelderblom HR, Siegert W Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant. 26,347–350 (2000).
   PubMed Web of Science ®Google Scholar
• Kadambi PV, Josephson MA, Williams J, Corey L, Jerome KR, Meehan SM, Limaye AR Treatment of refractory BK virus-associated nephropathy with cidofovir. Am. 7iamplant. 3,186-191 (2003).
   Google Scholar
• Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg. Infect. Dis. 8,891–896 (2002).
   PubMed Web of Science ®Google Scholar
• Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Bid Blood MarMW Transplant. 6,35-43 (2000). In this longitudinal cohort study, Vasconcelles and colleagues report that recipients of aerosolized pentamidine therapy had a higher incidence of PCP (odds ratio, 23.4), other serious non-PCP infections (OR 2.2) and overall mortality (OR 5.2) when compared with recipients of TMP/SMX prophylaxis. Daily dapsone appeared to be effective as secondary therapy for those who were not candidates for TMP/SMX.
   Google Scholar
• Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin. Infect. Dis. 29, 1467–1471 (1999).
   PubMed Web of Science ®Google Scholar
• Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 24,897–902 (1999).
   PubMed Web of Science ®Google Scholar
• Martino R, Bretagne S, Rovira M, etal. Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 25, 1111–1114 (2000).
   PubMed Web of Science ®Google Scholar
• Mele A, Paterson PJ, Prentice HG, Leoni P, Kibbler CC. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant. 29, 691–698 (2002).
   PubMed Web of Science ®Google Scholar
• Lewis JS Jr, Khoury H, Storch GA, DiPersio J. PCR for the diagnosis of toxoplasmosis after hematopoietic stem cell transplantation. Expert Rev Mal Diagn. 2, 616–624 (2002).
   PubMedGoogle Scholar
• Filicko J, Lazarus HM, Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant 31, 1–10 (2003).
   PubMed Web of Science ®Google Scholar